MRI device company Hyperfine Research Inc said on Monday that it plans the launch of the clinical research study of the world's first portable, low-cost magnetic resonance imaging (MRI) system in partnership with Penn Medicine.
Under the collaboration, Penn Medicine will examine the efficacy of the Hyperfine device in the care of patients with hydrocephalus, a medical condition in which an abnormal buildup of cerebrospinal fluid (CSF) causes the fluid-filled spaces of the brain to become enlarged. This can lead to headaches, dizziness, cognitive impairment, gait disturbances and in severe cases, even brain herniation or death.
In addition to assessing the feasibility of imaging patients with the new FDA 510(k)-pending system Hyperfine device, Penn Medicine will evaluate the Hyperfine system's diagnostic performance versus current high field MRI machines and computed tomography (CT) scanners.
The Hyperfine point-of-care (POC) device is highly portable and wheels directly to the patient's bedside, plugs into a standard electrical wall outlet and is controlled via an iPad. The system was developed with the goal of making MRI accessible anytime, anywhere, to any patient.
Additionally, Hyperfine is introducing its POC MRI system to the broader radiologist community at the Radiological Society of North America (RSNA) meeting on 1 December through 5 December at McCormick Place in Chicago, IL, Booth 7765 (North Hall).
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system